Home / Cardiovascular system / Atorvastatin and Amlodipine
ATC C10BX03 · Lipid Modifying Agents in Combination with Other Drugs
Atorvastatin and Amlodipine shortage
As of 2 Nov 2026, Atorvastatin and Amlodipine has a reported shortage in 2 of the 15 countries we track (Canada, Japan), covering 17 products from 5 companies.
Countries2/15
Products17packs or presentations
Companies53 listed
Short since11 Dec 202511 months ago
Earliest return8 Dec 2026company estimate
Main reasonIncreased demand
United StatesNo reported shortageCanada5 products shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapan12 products shortAustraliaNo reported shortage
Timeline
CanadaJapan
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: Viatris VTRS · Nasdaq, Sawai 4887 · Tokyo, Towa (Pensa) 4553 · Tokyo
Compared with similar medicines
ATC group C10BX · Lipid Modifying Agents in Combination with Other DrugsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | MYLAN-AMLODIPINE/ATORVASTATIN (1x90BTL) | MYLAN PHARMACEUTICALS ULC | 1 Aug 2026 | 8 Dec 2026 | Increased demand Demand increase for the drug |
| CA | MYLAN-AMLODIPINE/ATORVASTATIN (90BT) | MYLAN PHARMACEUTICALS ULC | 5 Aug 2026 | 8 Dec 2026 | Increased demand Demand increase for the drug |
| CA | CADUET (1x90 BTL CA) anticipated | BGP PHARMA ULC | 8 Nov 2026 | 8 Dec 2026 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | MYLAN-AMLODIPINE/ATORVASTATIN (1x90 BTL CA) anticipated | MYLAN PHARMACEUTICALS ULC | 17 Nov 2026 | 8 Dec 2026 | Increased demand Demand increase for the drug |
| CA | CADUET (1 x 90BTL) anticipated | BGP PHARMA ULC | 15 Dec 2026 | 12 Jan 2027 | Manufacturing problem Disruption of the manufacture of the drug |
| JP | アマルエット配合錠1番「サワイ」 limited | 沢井製薬 | 11 Dec 2025 | not given | Increased demand |
| JP | アマルエット配合錠2番「サワイ」 limited | 沢井製薬 | 11 Dec 2025 | not given | Increased demand |
| JP | アマルエット配合錠3番「サワイ」 limited | 沢井製薬 | 11 Dec 2025 | not given | Increased demand |
| JP | アマルエット配合錠4番「サワイ」 limited | 沢井製薬 | 11 Dec 2025 | not given | Increased demand |
| JP | アマルエット配合錠4番「日医工」 limited | 日医工 | 15 Dec 2025 | not given | Increased demand |
| JP | アマルエット配合錠3番「日医工」 limited | 日医工 | 13 Feb 2026 | not given | Increased demand |
| JP | アマルエット配合錠1番「トーワ」 | 東和薬品 | 18 Jun 2026 | not given | Manufacturing problem |
| JP | アマルエット配合錠2番「日医工」 limited | 日医工 | 25 Jun 2026 | not given | Increased demand |
| JP | アマルエット配合錠2番「トーワ」 | 東和薬品 | 9 Jul 2026 | not given | Manufacturing problem |
| JP | アマルエット配合錠1番「日医工」 | 日医工 | 9 Oct 2026 | not given | Quality problem or recall Quality problem |
| JP | アマルエット配合錠3番「トーワ」 limited | 東和薬品 | 22 Oct 2026 | not given | Manufacturing problem |
| JP | アマルエット配合錠4番「トーワ」 limited | 東和薬品 | 22 Oct 2026 | not given | Manufacturing problem |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.